We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division

AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division

AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division

AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AMRI Appoints Dr. Michael A. Guaciaro to Lead New Division "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Albany Molecular Research, Inc. has announced that Michael A. Guaciaro, Ph.D. has assumed leadership responsibility for the Hungarian facilities, and is relocating to Budapest.

ComGenex Chief Executive Officer Laszlo Urge, Ph.D. will remain with AMRI in Budapest and serve as a key member of the leadership team there.

Since joining AMRI in 2001, Dr. Guaciaro has led over 40 drug discovery project teams and has played a key role in the support and coordination of medicinal chemistry projects at the company's R&D centers in Singapore and India.

Prior to joining AMRI, Dr. Guaciaro worked at American Cyanamid Agricultural Research Center, where he was involved in the integration of research programs between sites in the United States and Europe. He obtained a Ph.D. in organic chemistry from the University of Pennsylvania

"Dr. Guaciaro is a veteran scientist with 25 years of professional industry experience and has created an impressive record of accomplishment during his tenure at AMRI," said D'Ambra.

"His research teams have discovered and developed several pre-clinical and clinical candidates in a number of therapeutic areas on behalf of our customers."

"We are pleased that Dr. Guaciaro has accepted this exciting opportunity to lead our European operations. I look forward to working closely with him as we continue to integrate ComGenex into the AMRI corporate family."

"We are also pleased that Dr. Urge has agreed to remain with AMRI. His experience and leadership will be critical, both during the short-term transition period and in helping us to achieve our long-range goals."

"He will be working closely with Dr. Guaciaro and the scientific team in Budapest to make this a successful effort."